Moderna shares jump 9% on leadership reshuffle and 2027-28 vaccine launch plans
Moderna stock surged 9% to nearly $57, marking a 94% gain year-to-date, driven by a leadership restructuring aimed at preparing for multiple vaccine launches in 2027 and 2028. The company expanded President Stephen Hoge's role and appointed Ester Ban...
